Eli Lilly completes eight-series note sale with approximately $8.94 billion net proceeds
Eli Lilly completed an offering of eight series of notes on May 20, 2026, with net proceeds of approximately $8.94 billion before estimated offering expenses. Maturities run from 2028 to 2066, and the filing ties five series to the proposed Centessa Acquisition, requiring their redemption at 101% of principal if that deal is not completed or the company says it will not pursue it.
Key points
- Net proceeds of approximately $8.94 billion before estimated offering expenses, per the filing.
- Fixed rate notes carry coupons from 4.150% (2029 notes) to 5.700% (2066 notes).
- Floating rate notes due 2028 and 2029 pay Compounded SOFR plus 0.350% and 0.460%, respectively.
- If the Centessa Acquisition is not completed by five business days after the later of March 31, 2027 or any agreed later Outside Date, the 2029 floating, 2029, 2031, 2033 and 2036 notes must be redeemed at 101% of principal plus accrued int
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.